

## Anticoagulation in device-detected atrial fibrillation with or without vascular disease A combined analysis of the NOAH-AFNET 6 and ARTESiA trials

### Supplementary Material

- A) Definition of indication for aspirin intake in NOAH-AFNET 6 and ARTESiA and  
B) number (%) of patients with this indication in the vascular disease subgroup.

A)

NOAH-AFNET 6	ARTESiA
<ul style="list-style-type: none"> <li>• Unstable angina pectoris</li> <li>• Acute myocardial infarction</li> <li>• Prevention of re-infarction</li> <li>• After arterial vascular or general surgical interventions (e.g. after coronary artery bypass grafting or after percutaneous transluminal coronary angioplasty)</li> <li>• For prevention of transitory ischemic attacks and strokes</li> </ul>	<ul style="list-style-type: none"> <li>• Stroke or transitory ischemic attack: stroke, transitory ischemic attack, unknown (no imaging)</li> <li>• Coronary artery disease: prior MI, prior percutaneous coronary intervention, prior coronary artery bypass grafting</li> <li>• Peripheral arterial disease: intermittent claudication, revascularization procedure</li> </ul>

B)

<b>NOAH-AFNET 6</b>	
<b>Indication</b>	<b>Number (%)</b>
Unstable angina pectoris	31 (2.3)
Acute myocardial infarction	79 (5.8)
Prior myocardial infarction	353 (25.9)
After arterial vascular or general surgical interventions (e.g. after coronary artery bypass grafting or after percutaneous coronary interventions)	502 (36.8)
For prevention of transitory ischemic attacks and strokes	445 (32.6)
<b>ARTESiA</b>	
<b>Indication</b>	<b>Number (%)</b>
Prior stroke or transient ischemic attack	346 (18.8)
Prior myocardial infarction	753 (40.9)
Prior coronary artery bypass grafting or percutaneous coronary intervention	904 (49.1)
Peripheral arterial disease	334 (18.1)